Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial

Phase 1positiveCMND-100Positive

AI Analysis

Summary

Clearmind Medicine reported positive early results from its ongoing Phase I/II trial of CMND-100 (MEAI), a non-hallucinogenic compound for alcohol use disorder, highlighted by principal investigators' positive early experience. The trial is a first-in-human study with real-world insights being shared.

Clinical Trial Data

Phase

Phase I/II

Outcome Details

Positive early experience highlighted by principal investigators

Importance:5/10

Sentiment:

0.65

Phase 1/2 TrialAlcohol Use DisorderNon-HallucinogenicFirst-in-HumanReal-World Data

Related Companies

$CMND

Read the original article

Published by GlobeNewswire Clinical Studies on July 13, 2026 12:17 PM

Read Original